On 1 October 2025 Denmark rolled out a nationwide program to vaccinate pregnant people against respiratory syncytial virus (RSV). The strategy aims to generate maternal antibodies that cross the placenta, offering newborns protection for roughly the first six months of life—the period when they are most vulnerable to severe RSV disease.
Impact on Infant Hospital Admissions
Caroline Klint Johannesen, a vaccine researcher at Nordsjællands Hospital in Hillerød, examined Danish health records from the winter following the policy’s introduction. She reported a dramatic decline in infant hospital admissions for RSV, describing the outcome as a clear indication that the immunizations are working. While the report does not provide exact figures, the observed drop is described as a “plummet,” suggesting a substantial reduction in severe cases that required hospitalization.
For newborns considered at high risk—such as premature infants whose mothers were not vaccinated—the program also includes administration of monoclonal antibodies. This dual approach ensures that the most vulnerable infants receive direct protection even when maternal vaccination is not possible.
Global Burden of RSV
The World Health Organization estimates that RSV leads to approximately 3.6 million hospitalizations and about 100 000 deaths among children under five each year. A striking 97 % of those deaths occur in low‑ and middle‑income countries, underscoring the disproportionate impact on regions with fewer health resources.
RSV also poses a serious threat to older adults, a risk that is often under‑recognized. Although global statistics for adult RSV mortality are lacking, the U.S. Centers for Disease Control and Prevention estimates that between 10 000 and 25 000 people have died from RSV in each of the past two winter seasons, with the highest mortality observed in individuals over 60 and those with chronic heart or lung conditions.
Advances in RSV Prevention
Since 2022, European regulators have approved nirsevimab, a long‑acting monoclonal antibody designed to protect infants against RSV. In addition, a second monoclonal antibody and three vaccines have been developed for adult use, including one formulation suitable for pregnant people. Pediatrician Buddy Creech of Vanderbilt University in Nashville, Tennessee, described the rapid expansion of preventive tools as “remarkable,” noting the shift from having “no mechanism to prevent RSV” to an “embarrassment of riches.”
Dozens of countries across Europe, Asia, and the Americas have already launched various RSV immunization programs, reflecting growing confidence in the vaccines and antibodies now available. Denmark’s experience provides a concrete example of how maternal vaccination can translate into measurable public‑health benefits, potentially guiding policy decisions in other regions confronting the virus’s heavy toll.
As more nations adopt similar strategies, the combined effect of maternal vaccines, infant monoclonal antibodies, and adult immunizations could reshape the global RSV landscape, reducing hospitalizations and saving lives across all age groups.
Mitchell Landsberg is a Senior Technology Correspondent at News Raise. He covers consumer electronics, artificial intelligence, software developments, and digital privacy trends.
